NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Arvinas, Inc. (ARVN) Stock Analysis

Arvinas, Inc. (ARVN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ARVN

$9.39

+$0.08 (+0.86%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARVN with… →

ARVN Key Statistics

As of Sep 4, 2026
Trading
Open
$9.31
Previous Close
$9.31
Day's Range
9.22–9.46
52-Week Range
6.97–14.51
Volume
449.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.76
Valuation
Market Cap
$605.85M
P/E Ratio
36.12
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.91
EPS (ttm)Profit attributable to each share over the last twelve months.
0.26
Financials (FY)
Revenue (FY)
$262.60M−0.30%
Net Income (FY)
−$80.80M
Profit marginThe share of revenue left as profit after all costs and taxes.
2.94%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
64.52M
1-Year Return
+23.39%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
769.54K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ARVN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−20.83%
2025−38.13%
2024−53.43%
2023+20.32%
2022−58.35%
2021−3.29%
2020+106.69%
2019+219.77%
2018 (partial year)−19.94%

As of September 4, 2026.

ARVN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$262.60M−$80.80M−30.8%
2024$263.40M−$198.90M−75.5%
2023$78.50M−$367.30M−467.9%
2022$131.40M−$282.50M−215.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$262.60M—−$118.50M−$80.80M−30.8%
2024$263.40M—−$250.20M−$198.90M−75.5%
2023$78.50M—−$401.50M−$367.30M−467.9%
2022$131.40M—−$263.20M−$282.50M−215.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ARVN Valuation vs Biotechnology Median

Median of 656 stocks
MetricARVNBiotechnology medianvs median
P/E36.1212.57187% above
P/S ratio1.9115.260.1x the median
Profit margin2.94%0.00%2.9 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Arvinas, Inc. (ARVN) at $605.85M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 246.

ARVN last closed at $9.39 on September 4, 2026. That is +$0.08 (+0.86%) against the previous close. The 52-week range on file runs from $6.97 to $14.51. The latest close sits 34.72% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $262.60M. That is −0.30% against the prior fiscal year, when revenue was $263.40M. The same year closed with a net loss of $80.80M. The reported profit margin is 2.94%. That is 2.9 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 0.26.

Across the 4 fiscal years on file, revenue moves from $131.40M in 2022 to $262.60M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 36.12. That is 187.35% above the Biotechnology median of 12.57. The price-to-sales ratio is 1.91. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +23.39%. Measured over 5 years, that is −35.77% a year compounded. The reported beta is 1.76. Daily returns over the trailing 7 years annualize to a volatility of 77.31%.

Growth & Income

The record shows no dividend for ARVN.

2026 is still running; the price is −20.83% year to date. The strongest complete calendar year on file is 2019 at +219.77%; the weakest is 2022 at −58.35%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Arvinas, Inc. (ARVN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Arvinas, Inc. ARVN $605.85M 36.1
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Arvinas, Inc. trades at a P/E of 36.1.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Arvinas, Inc.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Visit website →